The discovery of carcinogenic nitrosamine impurities in certain well-established antacid and blood pressure medicines implies that drug companies do not fully understand their products. Incidents such as these should serve as a wake-up call for regulators to review their age-old models for quality evaluation and result in a paradigm shift in how drug impurities are qualified.
These were the conclusions of a discussion at a recent industry conference in a session on establishing Europe as a...





